Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.
| Authors | Pramod K Mistry, Manisha Balwani, Hagit N Baris, Hadhami Ben Turkia, T Andrew Burrow, Joel Charrow, Gerald F Cox, Sumita Danda, Marta Dragosky, Guillermo Drelichman, Amal El-Beshlawy, Cristina Fraga, Selena Freisens, Sebastiaan Gaemers, Evgueniy Hadjiev, Priya S Kishnani, Elena Lukina, Pierre Maison-Blanche, Ana Maria Martins, Gregory Pastores, Milan Petakov, M Judith Peterschmitt, Hanna Rosenbaum, Barry Rosenbloom, Lisa H Underhill, Timothy M Cox |
| Journal | Blood cells, molecules & diseases
(Blood Cells Mol Dis)
Vol. 77
Pg. 101-102
(07 2019)
ISSN: 1096-0961 [Electronic] United States |
| PMID | 31029022
(Publication Type: Letter)
|
| Chemical References |
- Enzyme Inhibitors
- Pyrrolidines
- eliglustat
|
| Topics |
- Enzyme Inhibitors
(administration & dosage, adverse effects, therapeutic use)
- Gaucher Disease
(diagnosis, drug therapy)
- Humans
- Pyrrolidines
(administration & dosage, adverse effects, therapeutic use)
- Treatment Outcome
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|
